We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Spindle Assembly Checkpoint Proteins May Be Targeted by New Anticancer Drugs

By LabMedica International staff writers
Posted on 09 May 2012
Data published in a recent paper on the molecular factors that control chromosome segregation during cell division may help drug developers in their efforts to replace the taxane family of chemotherapeutic agents with similarly effective but less toxic drugs.

The primary taxane is paclitaxel, a naturally occurring compound originally extracted from the bark of the Pacific yew tree (Taxus spp.). More...
Due to high demand, paclitaxel is typically synthesized from the more abundant, naturally occurring compound 10-deacetyl baccatin III, which is extracted from the needles of yew plants. Paclitaxel and the closely related compound docetaxel disrupt microtubule function, which inhibits replication of cancer cells. However, this class of drug can have debilitating side effects including permanent neurological damage and hair loss.

Fine-tuning of drugs to replace the taxanes requires better understanding of the molecular processes that control chromosome segregation during cell division. To this end investigators at the University of Warwick (United Kingdom) have been studying the alphabet soup of proteins – including Mad1, Mad2, Mad3 (BubR1), Bub3, and the kinases Bub1, Mph1 (Mps1), and Aurora B – that comprise the spindle assembly checkpoint (SAC). SAC is the major surveillance system that ensures that sister chromatids do not separate until all chromosomes are correctly oriented during mitosis.

Details of how these proteins interact to maintain SAC activity were published in the April 19, 2012, online edition of the journal Current Biology.

Senior author Dr. Jonathan Millar, professor of cell biology at the University of Warwick said, “Components of the spindle assembly checkpoint were first discovered 22 years ago by researchers in America and yet, until now, the binding sites for these proteins on chromosomes have remained unknown. We have been able to answer this question and as a result, we are now in a much better position to design more selective and effective drugs. This research is a significant advance in our understanding of how the spindle checkpoint operates but it is really just the start. More research has to be done before we can convert this into a commercial treatment for patients. But we are greatly encouraged that our research here at Warwick is leading the way in the search for more effective cancer drugs.”

Related Links:

University of Warwick



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.